Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 22, Issue 8, Pages 1060-1073Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612822666151214125950
Keywords
Tryptophan; kynurenine; ischemia; stroke; neurodegeneration; depression; cognitive impairment; dementia
Categories
Funding
- Spanish Ministry of Economy and Competitiveness [SAF2012-33216, CSD2010-00045]
- Regional Madrid Government [S2010/BMD-2336]
- NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Kynurenines are a wide range of catabolites which derive from tryptophan through the Kynurenine Pathway (KP). In addition to its peripheral role, increasing evidence shows a role of the KP in the central nervous system (CNS), mediating both physiological and pathological functions. Indeed, an imbalance in this route has been associated with several neurodegenerative disorders such as Alzheimer's and Huntington's diseases. Altered KP catabolism has also been described during both acute and chronic phases of stroke; however the contribution of the KP to the pathophysiology of acute ischemic damage and of post-stroke disorders during the chronic phase including depression and vascular dementia, and the exact mechanisms implicated in the regulation of the KP after stroke are not well established yet. A better understanding of the regulation and activity of the KP after stroke could provide new pharmacological tools in both acute and chronic phases of stroke. In this review, we will make an overview of CNS modulation by the KP. We will detail the KP contribution in the ischemic damage, how the unbalance of the KP might trigger an alteration of the cognitive function after stroke as well as potential targets for the development of new drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available